Top Markets
Coin of the day
Zynerba Pharmaceuticals, Inc. Zynerba Pharmaceuticals, Inc.

Zynerba Pharmaceuticals, Inc.

ZYNE
株式のランク #26767
Zynerba Pharmaceuticals, Inc. is a specialized pharmaceutical firm currently in... Zynerba Pharmaceuticals, Inc. is a specialized pharmaceutical firm currently in the clinical development phase. Its primary objective is to create and advance medicinal transdermal cannabinoid treatments specifically for uncommon and scarcely encountered neuropsychiatric conditions. A key product in its pipeline is Zygel, a pharmaceutical-grade cannabidiol expertly crafted into a gel with enhanced skin penetration for topical application. Originally established as AllTranz, Inc., the company adopted its current name, Zynerba Pharmaceuticals, Inc., in August 2014. Founded in 2007, Zynerba Pharmaceuticals maintains its headquarters in Devon, Pennsylvania.
株価
$1.30
最終同期: 2023-10-13
時価総額
$38.02M
変化(1日)
0.00%
変化(1年)
0.00%
US
取引 Zynerba Pharmaceuticals, Inc. (ZYNE)

カテゴリー

Zynerba Pharmaceuticals, Inc.(ZYNE)の収益
Aug 2026 時点の収益 TTM: 0
Zynerba Pharmaceuticals, Inc. の最新の財務報告によると、現在の収益 (TTM) は 0 です。2026 年には 0 の収益があり、これは 2026 年の 0 と比較して 同等 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Zynerba Pharmaceuticals, Inc. の収益履歴(2026 ~ 2026)
各年末の収益
収益 変化
提供された日付のデータは十分ではありません。